GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Rhea-AI Summary
GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
CEO Dr. Marc Hertz will deliver a presentation on September 9, 2025, at 3:00 PM ET in New York. Management will also conduct one-on-one meetings with qualified investors during the conference. A live webcast will be available on the company's website, with the replay accessible for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – GRI
In the Sep 3 session, GRI gained 4.29%, reflecting a moderate positive market reaction. Argus tracked a peak move of +6.1% during that session. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live webcast presentation with CEO, Dr. Marc Hertz, on September 9th at 3:00 PM ET
LA JOLLA, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at 3:00 PM ET on Tuesday, September 9, 2025 at the H.C. Wainwright 27th Annual Global Investment Conference being held in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A live webcast of the presentation will be available on the Events page under the Investors section of the Company’s website (gribio.com). The webcast replay will be archived for 90 days following the event.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
